Baseline assessment
toxicity, D.L., Prostate Cancer, prostate cancer
PROSTATE CANCER, PROSTATE CANCER
Patients will be required to complete baseline assessments of toxicity by CTCAE v4.0, quality of life (QoL) related to prostate cancer by the Expanded Prostate Cancer Index Composite (EPIC), and baseline bloodwork to assess marrow, renal and hepatic function. Baseline bloodwork and urine samples will be collected as liquid biomarkers for future biomarker analysis. A hybrid PSMA PET/MRI will be done prior to randomization. As part of the PET/MRI, delayed PET images of the pelvis will be acquired at least 60 min after the PSMA ligand injection. MR images of the pelvis will be acquired, including T2 weighted, diffusion weighted, and dynamic contrast enhanced sequences. Imaging will be read by a certified Nuclear Medicine specialist (D.L.) experienced in PSMA PET/MRI and PET/CT interpretation using established interpretation schemes [